SINTX TECHNOLOGIES SIGNIFICANTLY STRENGTHENS ITS ANTIPATHOGENIC PATENT PORTFOLIO
January 04 2024 - 9:00AM
SINTX Technologies, Inc. (www.sintx.com) (NASDAQ: SINT; “SINTX” or
the “Company”), a manufacturer and developer of advanced ceramic
materials and related technologies, announced that it has been
granted its sixth United States patent in the last year. All of
these United States patents are related to the antipathogenic
properties of silicon nitride.
The six United States patents granted to SINTX
are:
- 11,591,217; Antipathogenic Devices
and Methods Thereof
- 11,672,252; Antifungal Composites
and Methods Thereof
- 11,738,122; Antibacterial
Biomedical Implants and Associated Materials, Apparatus, and
Methods
- 11,844,344; Systems and Methods for
Rapid Inactivation of SARS-COV-2 by Silicon Nitride and Aluminum
Nitride
- 11,850,214; Antiviral Compositions
and Devices and Methods of Use Thereof
- 11,857,001; Antipathogenic Face
Mask
The significance of the six mentioned patents
lies in their innovative approaches towards utilizing silicon
nitride (Si3N4) in a wide range of antipathogenic solutions. The
surface antipathogenic properties of silicon nitride have been
published extensively in the peer literature by SINTX as well as by
outside investigators.
The first two patents (US Patent Nos. 11,591,217
and 11,672,252) cover slurries and composites of silicon nitride
with polymethyl methacrylate (PMMA) for use in combating fungal
infections in plants and preventing fungal colonization of medical
implants - including specific applications in dentistry. The third
patent (US Patent No. 11,738,122) describes implants comprised of
polymeric and titanium materials coated with SiYAlON (a subclass of
silicon nitride materials) as well as implants made from composites
of SiYAlON and polymers like polyetheretherketone (PEEK) as
candidates for reducing infection burden in biomedical
applications. (These coating and composite technologies are the
foundation for recent and ongoing NIH-funded commercialization work
at SINTX.) The fourth patent (US Patent No. 11,844,344) presents a
method for rapid inactivation of viruses using silicon nitride in
various objects such as protective gear used by medical personnel.
The fifth patent (US Patent No. 11,850,214) extends the antiviral
composition to include various silicon nitride materials, thereby
offering versatility in forms like slurry or spray applicable to
medical devices. The final patent (US Patent No. 11,857,001)
emphasizes an antipathogenic face mask containing silicon nitride
and capable of inactivating human viruses.
The Company announced it has also received three
foreign patents on its proprietary technologies in 2023. SINTX has
forty-three patent applications that are currently pending around
the world including in the United States, Asia, Europe, and
Brazil.
“These patent grants and pending patent
applications reflect SINTX’s commitment to protecting the
intellectual property that has been created by the SINTX Research
and Development team”, said Dr. Ryan Bock, VP of R&D.
“Together, these patents showcase a wide range of innovative
applications of silicon nitride in addressing diverse pathogenic
challenges across various applications in agriculture, dentistry,
medical implants, durable medical equipment, and personal
protective equipment. We look forward to working with our current
and future partners in commercializing these technologies and
broadening the applications that benefit from silicon nitride.”
###
About SINTX Technologies,
Inc.
SINTX Technologies is an advanced ceramics
company that develops and commercializes materials, components, and
technologies for medical and technical applications. SINTX is a
global leader in the research, development, and manufacturing of
silicon nitride, and its products have been implanted in humans
since 2008. Over the past several years, SINTX has utilized
strategic acquisitions and alliances to enter into new markets. The
Company has manufacturing and R&D facilities in Utah and
Maryland.
For more information on SINTX Technologies or
its materials platform, visit www.sintx.com.
Forward-Looking Statements
This press release contains forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 (PSLRA), including, but not limited to,
statements regarding SINTX’s ability to effectively develop a range
of innovative applications of our silicon nitride formulations,
SINTX’s ability to commercialize its technologies and broaden the
applications that benefit from silicon nitride, and other
statements that are not based on historical fact. Such
forward-looking statements are subject to a number of risks and
uncertainties that may cause actual results to differ from current
expectations. Risks and uncertainties that may cause such
differences include, among other things: SINTX’s products may not
prove to be as effective as other products currently being
commercialized or to be commercialized in the future by
competitors; risks inherent in manufacturing and scaling up to
commercial quantities while maintaining quality controls and
qualification standards; the uncertainties inherent in new product
development, including the cost and time required to commercialize
such product(s); market acceptance of SINTX’s products once
commercialized; risks related to manufacturing products and market
acceptance volatility in the price of SINTX’s common stock; SINTX’s
ability to raise funding and other competitive developments.
Readers are cautioned not to place undue reliance on the
forward-looking statements, which speak only as of the date on
which they are made and reflect management’s current estimates,
projections, expectations and beliefs. There can be no assurance
that any of the anticipated results will occur on a timely basis or
at all due to certain risks and uncertainties, a discussion of
which can be found in SINTX’s Risk Factors disclosure in its Annual
Report on Form 10-K, filed with the Securities and Exchange
Commission (SEC) on March 29, 2023, and in SINTX’s other filings
with the SEC. SINTX disclaims any obligation to update any
forward-looking statements. SINTX undertakes no obligation to
publicly revise or update the forward-looking statements to reflect
events or circumstances that arise after the date of this
report.
Business and Media Inquiries for SINTX:SINTX
Technologies801.839.3502IR@sintx.com
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Jun 2024 to Jul 2024
SiNtx Technologies (NASDAQ:SINT)
Historical Stock Chart
From Jul 2023 to Jul 2024